Objectives This study examined the effectiveness of nirmatrelvir plus ritonavir (NMV-r) and
molnupiravir (MOV) in treating COVID-19 among chronic kidney disease (CKD) patients …

Background Nirmatrelvir-ritonavir is used in patients with coronavirus disease 2019 (COVID-
19) with normal or mild renal impairment (eGFR≥ 30 ml/min per 1.73 m 2). There is limited …

Background: Chronic kidney disease (CKD) is a mortality risk factor for COVID-19,
predisposing patients to poor clinical outcomes. Nirmatrelvir/ritonavir (Nm/r) is currently the …

As of December 2022, over 651 million people have been diagnosed with coronavirus
disease 2019 (COVID-19) and 6.6 million people have died of COVID-19 [1]. Chronic kidney …

Introduction Even with effective vaccines, patients with CKD have a higher risk of
hospitalization and death subsequent to COVID-19 infection compared with those without …

Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with
coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of …

Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid),
Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus …

Background Nirmatrelvir-ritonavir is currently not recommended in patients with an
estimated glomerular filtration rate (eGFR)< 30 mL/minute/1.73 m2. Methods To determine …

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, it has been
clear that patients with CKD and kidney failure treated with dialysis are at high risk of …

Background Nirmatrelvir/ritonavir was approved for use in high-risk outpatients with
coronavirus disease 2019 (COVID-19). However, patients with severe CKD were excluded …